A Novel Test to Measure Response to Treatment of a CF Pulmonary Exacerbation
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Inflammation is present in the Cystic Fibrosis(CF) airway from the time of infancy, and worsens with the onset of chronic lung infection. Therapies that reduce airway inflammation have proven beneficial. THis study is looking at a blood test measuring changes in white blood cell protein to see if this may be a sensitive indicator of airway inflammation that could be used in care and research.
18 Years - 999 Years
1 - 99 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
National Jewish Health (Adult), Denver, CO, 80206
Jones, Marion Phone: (303) 398-1265 Email: email@example.com